JP2017513477A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017513477A5 JP2017513477A5 JP2016562503A JP2016562503A JP2017513477A5 JP 2017513477 A5 JP2017513477 A5 JP 2017513477A5 JP 2016562503 A JP2016562503 A JP 2016562503A JP 2016562503 A JP2016562503 A JP 2016562503A JP 2017513477 A5 JP2017513477 A5 JP 2017513477A5
- Authority
- JP
- Japan
- Prior art keywords
- cell
- cells
- dna
- nucleic acids
- isolated
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 claims description 101
- 210000004027 cell Anatomy 0.000 claims description 80
- 108020004414 DNA Proteins 0.000 claims description 55
- 230000004048 modification Effects 0.000 claims description 33
- 238000012986 modification Methods 0.000 claims description 33
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 22
- 150000007523 nucleic acids Chemical class 0.000 claims description 20
- 238000004520 electroporation Methods 0.000 claims description 18
- 239000000203 mixture Substances 0.000 claims description 18
- 108020004707 nucleic acids Proteins 0.000 claims description 18
- 102000039446 nucleic acids Human genes 0.000 claims description 18
- 210000000130 stem cell Anatomy 0.000 claims description 9
- 101710163270 Nuclease Proteins 0.000 claims description 8
- 230000003833 cell viability Effects 0.000 claims description 8
- 239000003795 chemical substances by application Substances 0.000 claims description 6
- 210000004962 mammalian cell Anatomy 0.000 claims description 6
- 229940124568 digestive agent Drugs 0.000 claims description 5
- 210000003958 hematopoietic stem cell Anatomy 0.000 claims description 5
- 108020004705 Codon Proteins 0.000 claims description 4
- 108091034117 Oligonucleotide Proteins 0.000 claims description 4
- 238000012216 screening Methods 0.000 claims description 4
- 238000001890 transfection Methods 0.000 claims description 4
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 3
- 230000001902 propagating effect Effects 0.000 claims description 3
- 102000040650 (ribonucleotides)n+m Human genes 0.000 claims description 2
- 108091033409 CRISPR Proteins 0.000 claims description 2
- 108020005004 Guide RNA Proteins 0.000 claims description 2
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 claims description 2
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 claims description 2
- 102100034343 Integrase Human genes 0.000 claims description 2
- 108010061833 Integrases Proteins 0.000 claims description 2
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 2
- 238000010459 TALEN Methods 0.000 claims description 2
- 108010043645 Transcription Activator-Like Effector Nucleases Proteins 0.000 claims description 2
- 102000008579 Transposases Human genes 0.000 claims description 2
- 108010020764 Transposases Proteins 0.000 claims description 2
- 230000004075 alteration Effects 0.000 claims description 2
- 210000001185 bone marrow Anatomy 0.000 claims description 2
- 239000002458 cell surface marker Substances 0.000 claims description 2
- 238000010790 dilution Methods 0.000 claims description 2
- 239000012895 dilution Substances 0.000 claims description 2
- 210000002950 fibroblast Anatomy 0.000 claims description 2
- 230000008014 freezing Effects 0.000 claims description 2
- 238000007710 freezing Methods 0.000 claims description 2
- 210000005260 human cell Anatomy 0.000 claims description 2
- 238000011031 large-scale manufacturing process Methods 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 210000002901 mesenchymal stem cell Anatomy 0.000 claims description 2
- 239000002773 nucleotide Substances 0.000 claims description 2
- 125000003729 nucleotide group Chemical group 0.000 claims description 2
- 210000005105 peripheral blood lymphocyte Anatomy 0.000 claims description 2
- 239000012679 serum free medium Substances 0.000 claims description 2
- 230000003612 virological effect Effects 0.000 claims description 2
- 102000053602 DNA Human genes 0.000 claims 1
- 108020004682 Single-Stranded DNA Proteins 0.000 claims 1
- 230000008685 targeting Effects 0.000 claims 1
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 101150013707 HBB gene Proteins 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 102100025621 Cytochrome b-245 heavy chain Human genes 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 208000016532 chronic granulomatous disease Diseases 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461979178P | 2014-04-14 | 2014-04-14 | |
| US61/979,178 | 2014-04-14 | ||
| US201462078706P | 2014-11-12 | 2014-11-12 | |
| US62/078,706 | 2014-11-12 | ||
| PCT/US2015/025523 WO2015160683A1 (en) | 2014-04-14 | 2015-04-13 | Methods and compositions for modifying genomic dna |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020127917A Division JP7209671B2 (ja) | 2014-04-14 | 2020-07-29 | ゲノムｄｎａを改変するための方法および組成物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2017513477A JP2017513477A (ja) | 2017-06-01 |
| JP2017513477A5 true JP2017513477A5 (enExample) | 2018-05-24 |
Family
ID=54324457
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016562503A Pending JP2017513477A (ja) | 2014-04-14 | 2015-04-13 | ゲノムｄｎａを改変するための方法および組成物 |
| JP2020127917A Active JP7209671B2 (ja) | 2014-04-14 | 2020-07-29 | ゲノムｄｎａを改変するための方法および組成物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020127917A Active JP7209671B2 (ja) | 2014-04-14 | 2020-07-29 | ゲノムｄｎａを改変するための方法および組成物 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20170029805A1 (enExample) |
| EP (1) | EP3132025B1 (enExample) |
| JP (2) | JP2017513477A (enExample) |
| KR (1) | KR102406585B1 (enExample) |
| CN (1) | CN106687585B (enExample) |
| ES (1) | ES2962509T3 (enExample) |
| SG (1) | SG11201608503UA (enExample) |
| WO (1) | WO2015160683A1 (enExample) |
Families Citing this family (79)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013066438A2 (en) | 2011-07-22 | 2013-05-10 | President And Fellows Of Harvard College | Evaluation and improvement of nuclease cleavage specificity |
| EP2970915B1 (en) | 2013-03-15 | 2019-08-14 | Maxcyte, Inc. | Methods and compositions for generating stable transfected cells |
| US9163284B2 (en) | 2013-08-09 | 2015-10-20 | President And Fellows Of Harvard College | Methods for identifying a target site of a Cas9 nuclease |
| US9359599B2 (en) | 2013-08-22 | 2016-06-07 | President And Fellows Of Harvard College | Engineered transcription activator-like effector (TALE) domains and uses thereof |
| US9340799B2 (en) | 2013-09-06 | 2016-05-17 | President And Fellows Of Harvard College | MRNA-sensing switchable gRNAs |
| US9322037B2 (en) | 2013-09-06 | 2016-04-26 | President And Fellows Of Harvard College | Cas9-FokI fusion proteins and uses thereof |
| US9526784B2 (en) | 2013-09-06 | 2016-12-27 | President And Fellows Of Harvard College | Delivery system for functional nucleases |
| US10584358B2 (en) | 2013-10-30 | 2020-03-10 | North Carolina State University | Compositions and methods related to a type-II CRISPR-Cas system in Lactobacillus buchneri |
| CN111218447B (zh) | 2013-11-07 | 2024-10-11 | 爱迪塔斯医药有限公司 | 使用统治型gRNA的CRISPR相关方法和组合物 |
| US20150166984A1 (en) | 2013-12-12 | 2015-06-18 | President And Fellows Of Harvard College | Methods for correcting alpha-antitrypsin point mutations |
| US10787654B2 (en) | 2014-01-24 | 2020-09-29 | North Carolina State University | Methods and compositions for sequence guiding Cas9 targeting |
| EP3129490A4 (en) | 2014-04-08 | 2017-10-04 | North Carolina State University | Methods and compositions for rna-directed repression of transcription using crispr-associated genes |
| GB201407852D0 (en) | 2014-05-02 | 2014-06-18 | Iontas Ltd | Preparation of libraries od protein variants expressed in eukaryotic cells and use for selecting binding molecules |
| AU2015298571B2 (en) | 2014-07-30 | 2020-09-03 | President And Fellows Of Harvard College | Cas9 proteins including ligand-dependent inteins |
| US10450584B2 (en) | 2014-08-28 | 2019-10-22 | North Carolina State University | Cas9 proteins and guiding features for DNA targeting and genome editing |
| EP3204496A1 (en) | 2014-10-10 | 2017-08-16 | Editas Medicine, Inc. | Compositions and methods for promoting homology directed repair |
| WO2016073990A2 (en) | 2014-11-07 | 2016-05-12 | Editas Medicine, Inc. | Methods for improving crispr/cas-mediated genome-editing |
| US11608511B2 (en) | 2015-04-13 | 2023-03-21 | Maxcyte, Inc. | Methods for modifying genomic DNA |
| WO2016196361A1 (en) | 2015-05-29 | 2016-12-08 | North Carolina State University | Methods for screening bacteria, archaea, algae, and yeast using crispr nucleic acids |
| AU2016280002B2 (en) | 2015-06-15 | 2022-04-14 | North Carolina State University | Methods and compositions for efficient delivery of nucleic acids and RNA-based antimicrobials |
| CA2999500A1 (en) | 2015-09-24 | 2017-03-30 | Editas Medicine, Inc. | Use of exonucleases to improve crispr/cas-mediated genome editing |
| US11286480B2 (en) | 2015-09-28 | 2022-03-29 | North Carolina State University | Methods and compositions for sequence specific antimicrobials |
| WO2017070632A2 (en) | 2015-10-23 | 2017-04-27 | President And Fellows Of Harvard College | Nucleobase editors and uses thereof |
| US9988624B2 (en) | 2015-12-07 | 2018-06-05 | Zymergen Inc. | Microbial strain improvement by a HTP genomic engineering platform |
| WO2017112620A1 (en) | 2015-12-22 | 2017-06-29 | North Carolina State University | Methods and compositions for delivery of crispr based antimicrobials |
| WO2017165826A1 (en) | 2016-03-25 | 2017-09-28 | Editas Medicine, Inc. | Genome editing systems comprising repair-modulating enzyme molecules and methods of their use |
| US11236313B2 (en) | 2016-04-13 | 2022-02-01 | Editas Medicine, Inc. | Cas9 fusion molecules, gene editing systems, and methods of use thereof |
| US20190247436A1 (en) * | 2016-07-21 | 2019-08-15 | Maxcyte, Inc. | Methods and compositions for modifying genomic dna |
| JP7179715B2 (ja) * | 2016-07-27 | 2022-11-29 | ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー | 核酸送達用の崩壊性細胞透過性複合体 |
| WO2018027078A1 (en) | 2016-08-03 | 2018-02-08 | President And Fellows Of Harard College | Adenosine nucleobase editors and uses thereof |
| AU2017308889B2 (en) | 2016-08-09 | 2023-11-09 | President And Fellows Of Harvard College | Programmable Cas9-recombinase fusion proteins and uses thereof |
| WO2018039438A1 (en) | 2016-08-24 | 2018-03-01 | President And Fellows Of Harvard College | Incorporation of unnatural amino acids into proteins using base editing |
| KR20240007715A (ko) | 2016-10-14 | 2024-01-16 | 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 | 핵염기 에디터의 aav 전달 |
| WO2018119359A1 (en) | 2016-12-23 | 2018-06-28 | President And Fellows Of Harvard College | Editing of ccr5 receptor gene to protect against hiv infection |
| WO2018165504A1 (en) | 2017-03-09 | 2018-09-13 | President And Fellows Of Harvard College | Suppression of pain by gene editing |
| KR20190123328A (ko) | 2017-03-09 | 2019-10-31 | 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 | 암 백신 |
| CN110914310A (zh) | 2017-03-10 | 2020-03-24 | 哈佛大学的校长及成员们 | 胞嘧啶至鸟嘌呤碱基编辑器 |
| IL306092A (en) | 2017-03-23 | 2023-11-01 | Harvard College | Nucleic base editors that include nucleic acid programmable DNA binding proteins |
| US11560566B2 (en) | 2017-05-12 | 2023-01-24 | President And Fellows Of Harvard College | Aptazyme-embedded guide RNAs for use with CRISPR-Cas9 in genome editing and transcriptional activation |
| CN111032867A (zh) * | 2017-06-16 | 2020-04-17 | 应用干细胞有限公司 | 具有提高的敲入效率的基因编辑方法 |
| MX2019015505A (es) | 2017-06-30 | 2020-07-28 | Inscripta Inc | Metodos, modulos, instrumentos y sistemas de procesamiento de celulas automatizados. |
| EP3652312A1 (en) | 2017-07-14 | 2020-05-20 | Editas Medicine, Inc. | Systems and methods for targeted integration and genome editing and detection thereof using integrated priming sites |
| EP3658573A1 (en) | 2017-07-28 | 2020-06-03 | President and Fellows of Harvard College | Methods and compositions for evolving base editors using phage-assisted continuous evolution (pace) |
| US10738327B2 (en) | 2017-08-28 | 2020-08-11 | Inscripta, Inc. | Electroporation cuvettes for automation |
| EP3676376B1 (en) | 2017-08-30 | 2025-01-15 | President and Fellows of Harvard College | High efficiency base editors comprising gam |
| US10435713B2 (en) | 2017-09-30 | 2019-10-08 | Inscripta, Inc. | Flow through electroporation instrumentation |
| CA3082251A1 (en) | 2017-10-16 | 2019-04-25 | The Broad Institute, Inc. | Uses of adenosine base editors |
| US12406749B2 (en) | 2017-12-15 | 2025-09-02 | The Broad Institute, Inc. | Systems and methods for predicting repair outcomes in genetic engineering |
| BR112020014989A2 (pt) * | 2018-02-01 | 2020-12-29 | Institute Of Genetics And Developmental Biology, Chinese Academy Of Sciences | Método aprimorado para edição de genoma |
| US10443031B1 (en) | 2018-03-29 | 2019-10-15 | Inscripta, Inc. | Methods for controlling the growth of prokaryotic and eukaryotic cells |
| WO2019200004A1 (en) | 2018-04-13 | 2019-10-17 | Inscripta, Inc. | Automated cell processing instruments comprising reagent cartridges |
| US10858761B2 (en) | 2018-04-24 | 2020-12-08 | Inscripta, Inc. | Nucleic acid-guided editing of exogenous polynucleotides in heterologous cells |
| US10557216B2 (en) | 2018-04-24 | 2020-02-11 | Inscripta, Inc. | Automated instrumentation for production of T-cell receptor peptide libraries |
| US10508273B2 (en) | 2018-04-24 | 2019-12-17 | Inscripta, Inc. | Methods for identifying selective binding pairs |
| WO2019226953A1 (en) | 2018-05-23 | 2019-11-28 | The Broad Institute, Inc. | Base editors and uses thereof |
| EP3820495A4 (en) | 2018-07-09 | 2022-07-20 | The Broad Institute Inc. | RNA-PROGRAMMABLE EPIGENETIC RNA MODIFIERS AND THEIR USES |
| US10532324B1 (en) | 2018-08-14 | 2020-01-14 | Inscripta, Inc. | Instruments, modules, and methods for improved detection of edited sequences in live cells |
| US11142740B2 (en) | 2018-08-14 | 2021-10-12 | Inscripta, Inc. | Detection of nuclease edited sequences in automated modules and instruments |
| US10752874B2 (en) | 2018-08-14 | 2020-08-25 | Inscripta, Inc. | Instruments, modules, and methods for improved detection of edited sequences in live cells |
| IL292273B2 (en) | 2018-08-14 | 2023-10-01 | Inscripta Inc | Devices, modules and methods for improved detection of edited sequences in living cells |
| CA3108892A1 (en) | 2018-08-30 | 2020-04-23 | Inscripta, Inc. | Improved detection of nuclease edited sequences in automated modules and instruments |
| US12203123B2 (en) | 2018-10-01 | 2025-01-21 | North Carolina State University | Recombinant type I CRISPR-Cas system and uses thereof for screening for variant cells |
| US10711267B2 (en) | 2018-10-01 | 2020-07-14 | North Carolina State University | Recombinant type I CRISPR-Cas system |
| WO2020072250A1 (en) | 2018-10-01 | 2020-04-09 | North Carolina State University | Recombinant type i crispr-cas system and uses thereof for genome modification and alteration of expression |
| US12264330B2 (en) | 2018-10-01 | 2025-04-01 | North Carolina State University | Recombinant type I CRISPR-Cas system and uses thereof for killing target cells |
| WO2020092453A1 (en) | 2018-10-29 | 2020-05-07 | The Broad Institute, Inc. | Nucleobase editors comprising geocas9 and uses thereof |
| EP3898967A1 (en) | 2018-12-17 | 2021-10-27 | Consejo Superior de Investigaciones Científicas (CSIC) | Method for the introduction of genetic information in cell by site-specific integration system |
| US12351837B2 (en) | 2019-01-23 | 2025-07-08 | The Broad Institute, Inc. | Supernegatively charged proteins and uses thereof |
| WO2020191241A1 (en) | 2019-03-19 | 2020-09-24 | The Broad Institute, Inc. | Methods and compositions for editing nucleotide sequences |
| WO2020214842A1 (en) | 2019-04-17 | 2020-10-22 | The Broad Institute, Inc. | Adenine base editors with reduced off-target effects |
| US10907125B2 (en) | 2019-06-20 | 2021-02-02 | Inscripta, Inc. | Flow through electroporation modules and instrumentation |
| CN114008070A (zh) | 2019-06-21 | 2022-02-01 | 因思科瑞普特公司 | 导致大肠杆菌赖氨酸产量增加的全基因组合理设计的突变 |
| US10927385B2 (en) | 2019-06-25 | 2021-02-23 | Inscripta, Inc. | Increased nucleic-acid guided cell editing in yeast |
| US12435330B2 (en) | 2019-10-10 | 2025-10-07 | The Broad Institute, Inc. | Methods and compositions for prime editing RNA |
| US10689669B1 (en) | 2020-01-11 | 2020-06-23 | Inscripta, Inc. | Automated multi-module cell processing methods, instruments, and systems |
| CN115135370A (zh) | 2020-01-27 | 2022-09-30 | 因思科瑞普特公司 | 电穿孔模块和仪器 |
| US20210332388A1 (en) | 2020-04-24 | 2021-10-28 | Inscripta, Inc. | Compositions, methods, modules and instruments for automated nucleic acid-guided nuclease editing in mammalian cells |
| CA3177481A1 (en) | 2020-05-08 | 2021-11-11 | David R. Liu | Methods and compositions for simultaneous editing of both strands of a target double-stranded nucleotide sequence |
| US11787841B2 (en) | 2020-05-19 | 2023-10-17 | Inscripta, Inc. | Rationally-designed mutations to the thrA gene for enhanced lysine production in E. coli |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2001289104A1 (en) * | 2000-09-15 | 2002-03-26 | Deltagen, Inc. | Methods of producing cells and animals comprising targeted gene modifications |
| DK2574662T3 (da) * | 2001-08-22 | 2021-09-20 | Maxcyte Inc | Fremgangsmåde til elektroporation af biologiske prøver |
| US20080311095A1 (en) * | 2007-05-23 | 2008-12-18 | Sangamo Biosciences, Inc. | Methods and compositions for increased transgene expression |
| WO2007030674A2 (en) * | 2005-09-07 | 2007-03-15 | Maxcyte, Inc. | Use of nucleases to improve viability and enhance transgene expression in transfected cells |
| CA2648778A1 (en) * | 2006-04-10 | 2007-10-18 | The Regents Of The University Of California | Method for culturing cells on removable pallets for subsequent cell expansion and analysis |
| WO2012012738A1 (en) * | 2010-07-23 | 2012-01-26 | Sigma-Aldrich Co., Llc | Genome editing using targeting endonucleases and single-stranded nucleic acids |
| US9222105B2 (en) * | 2011-10-27 | 2015-12-29 | Sangamo Biosciences, Inc. | Methods and compositions for modification of the HPRT locus |
| WO2013139994A1 (en) * | 2012-03-23 | 2013-09-26 | Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) | A novel method of producing an oocyte carrying a modified target sequence in its genome |
| CA2871524C (en) * | 2012-05-07 | 2021-07-27 | Sangamo Biosciences, Inc. | Methods and compositions for nuclease-mediated targeted integration of transgenes |
| KR20150023670A (ko) * | 2012-06-12 | 2015-03-05 | 제넨테크, 인크. | 조건적 녹아웃 대립유전자의 생성 방법 및 이를 위한 조성물 |
| CN102839214A (zh) * | 2012-09-06 | 2012-12-26 | 许汉鹏 | 筛选真核细胞基因组内特定基因调控相关机制和分子的方法 |
| EP2970915B1 (en) * | 2013-03-15 | 2019-08-14 | Maxcyte, Inc. | Methods and compositions for generating stable transfected cells |
| JP6608807B2 (ja) * | 2013-05-29 | 2019-11-20 | セレクティス | Ｒｎａガイドｃａｓヌクレアーゼ系を用いることによって免疫療法のためにｔ細胞を操作するための方法 |
-
2015
- 2015-04-13 ES ES15780038T patent/ES2962509T3/es active Active
- 2015-04-13 EP EP15780038.4A patent/EP3132025B1/en active Active
- 2015-04-13 KR KR1020167031636A patent/KR102406585B1/ko active Active
- 2015-04-13 SG SG11201608503UA patent/SG11201608503UA/en unknown
- 2015-04-13 JP JP2016562503A patent/JP2017513477A/ja active Pending
- 2015-04-13 US US15/303,932 patent/US20170029805A1/en not_active Abandoned
- 2015-04-13 CN CN201580025136.0A patent/CN106687585B/zh active Active
- 2015-04-13 WO PCT/US2015/025523 patent/WO2015160683A1/en not_active Ceased
-
2020
- 2020-07-29 JP JP2020127917A patent/JP7209671B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019520844A5 (enExample) | ||
| JP7209671B2 (ja) | ゲノムｄｎａを改変するための方法および組成物 | |
| JP2018512162A5 (enExample) | ||
| JP7197363B2 (ja) | ヌクレアーゼを使用するヒト神経幹細胞のゲノム編集 | |
| EP3445388B1 (en) | Materials and methods for treatment of hemoglobinopathies | |
| JP2022153470A (ja) | ゲノムｄｎａを改変するための方法および組成物 | |
| CN107893076A (zh) | CRISPR‑Cas9靶向敲除人乳腺癌细胞RASSF2基因及其特异性的sgRNA | |
| CN106701830A (zh) | 一种敲除猪胚胎p66shc基因的方法 | |
| CN116064386A (zh) | 永生化干细胞及其制作方法 | |
| EP4419672A2 (en) | Compositions and methods for targeting, editing, or modifying genes | |
| CN112941106B (zh) | 一种通过foxp1基因编辑和突变延缓间充质干细胞衰老的方法 | |
| CN119979470A (zh) | 一种可体外长期培养的猪肌肉干细胞细胞系及其应用 | |
| CN104745551B (zh) | 利用talen敲除人乳头瘤病毒e6e7癌基因的方法 | |
| CN110616233A (zh) | CRISPR-Cas9高效敲除原代T细胞基因的方法及其应用 | |
| CN110229816B (zh) | 用于敲除RBP4基因的sgRNA、RBP4基因缺失细胞株的构建方法及应用 | |
| US20260071238A1 (en) | Materials and processes for engineering hypoimmunogenicity | |
| US20250115903A1 (en) | Compositions and methods for editing genomes | |
| CN111793606B (zh) | 一种提高CRISPR/Cas9介导的同源修复效率的方法 | |
| CN110241135B (zh) | 促进基因编辑的化合物筛选和鉴定及其应用 | |
| CN106967686B (zh) | 软骨细胞体外端粒延长增殖培养的方法及人源组织工程化再生软骨 | |
| Bennett et al. | 12 Detection of Insertion/Deletion (Indel) Events after Genome Targeting: Pros and Cons of the Available Methods | |
| US20250222103A1 (en) | Immune cells with combination gene perturbations | |
| WO2019173615A1 (en) | Sphingolipid-metabolizing proteins enhance the efficiency of gene editing in cells | |
| CN106957820A (zh) | 体外软骨细胞端粒延长增殖培养用培养基、试剂盒和应用 | |
| JP2026504098A (ja) | 新規ポリヌクレオチド、細胞及び方法 |